JIUYUAN GENE's stock plummeted 5.08% during intraday trading on Tuesday, following the release of its full-year 2025 financial results which showed a decline in revenue.

The company reported that revenue for FY25 slipped 4.6% to RMB 1.3 billion. The decline was driven mainly by lower orthopedic product sales, attributed to ongoing DRGs/DIP healthcare payment reforms and online listing-related price cuts which pressured the business.

While the company's gross margin widened by 1.7 percentage points to 80.7% due to lower raw material costs and lean production management, and profit attributable to owners remained largely unchanged at RMB 138 million, the top-line contraction appears to have concerned investors, leading to the significant sell-off during the trading session.